The tandem BRCT domains of BRCA1 and MDC1 facilitate protein signaling at DNA damage foci through specific interactions with serine-phosphorylated protein partners. The MDC1 BRCT binds pSerGln-Glu-Tyr-COO À at the C terminus of the histone variant gH2AX via direct recognition of the C-terminal carboxylate, while BRCA1 recognizes pSer-X-X-Phe motifs either at C-terminal or internal sites within target proteins. Using fluorescence polarization binding assays, we show that while both BRCTs prefer a free main chain carboxylate at the +3 position, this preference is much more pronounced in MDC1. Crystal structures of BRCA1 and MDC1 bound to tetrapeptide substrates reveal differences in the environment of conserved arginines (Arg1699 in BRCA1 and Arg1933 in MDC1) that determine the relative affinity for peptides with -COO À versus -CO-NH 2 termini. A mutation in MDC1 that induces a more BRCA1-like conformation relaxes the binding specificity, allowing the mutant to bind phosphopeptides lacking a -COO À terminus.
INTRODUCTION
The maintenance of genomic integrity in the face of genotoxic events relies on nuclear signaling systems that coordinate the repair of DNA damage with regulation of the cell cycle and apoptosis. Protein phosphorylation plays a central part in these signaling pathways, involving conserved Ser/Thr protein kinases and classes of proteins that have evolved to specifically recognize phosphorylated protein targets (Mohammad and Yaffe, 2009) .
One of the most important classes of protein modules that recognize phosphoproteins in the DNA damage response are BRCT domains, named after the tandem repeats found at the C terminus of the breast cancer-associated protein, BRCA1 (Callebaut and Mornon, 1997; Koonin et al., 1996; Miki et al., 1994) . This region is critical to the tumor suppressor function of BRCA1, as cancer-associated mutations tend to cluster in this region of the protein (Easton et al., 2007; Futreal et al., 1994; Miki et al., 1994) . The tandem BRCA1 BRCT repeats pack in a head-to-tail manner (Williams et al., 2001) , forming a single protein domain that specifically binds peptide motifs containing a phosphoserine followed by a phenylalanine 3 residues toward the C terminus (Manke et al., 2003) ( Figure 1A ). Recognition of pSer-x-x-Phe motifs govern interactions between BRCA1 and target proteins such as the BRIP1/BACH1 DNA helicase (Yu et al., 2003) , the DNA end processing nuclease CtIP (Yu and Chen, 2004) , and the double strand break-associated protein Abraxas (Kim et al., 2007; Liu et al., 2007; Wang et al., 2007) . The phosphoserine of the peptide target is recognized by a cluster of residues in the N-terminal BRCT repeat that provides ligands for the phosphate, while the phenylalanine is recognized by a pronounced pocket at the interface of the two repeats (Clapperton et al., 2004; Glover et al., 2004; Shiozaki et al., 2004; Williams et al., 2004) (Figure 1B ). Critical for recognition of the phenylalanine is Arg1699, which interacts with the main chain of the peptide phenylalanine, positioning the side chain in the hydrophobic recognition pocket. The phenylalanine recognition pocket is essential for BRCA1 tumor suppression as is illustrated by the finding that the missense mutant M1775R specifically perturbs the structure of this pocket and abrogates phosphopeptide recognition (Williams and Glover, 2003) .
Another BRCT protein, MDC1, plays an essential early role in signaling from DNA double strand breaks through its recognition of the ATM-phosphophorylated histone variant, H2AX (Goldberg et al., 2003; Lou et al., 2003; Stewart et al., 2003) . Phospho-H2AX (also known as gH2AX) ultimately leads to the recruitment of DNA repair, replication, and cell cycle regulatory factors to the site of the damage (Sedelnikova et al., 2003; Stucki and Jackson, 2006) . The C-terminal phosphorylated tail of gH2AX serves as the specific binding site for MDC1 (Lee et al., 2005; Stucki et al., 2005) , which initiates a cascade of phosphorylation and ubiquitination events that recruit BRCA1 to the double strand break foci (Yan and Jetten, 2008) .
Intriguingly, the BRCA1 and MDC1 tandem BRCT repeats recognize very similar phosphopeptide substrates: pSer-x-xPhe/Tyr for BRCA1 and pSer-Gln-Glu-Tyr for MDC1. In spite of this similarity, MDC1 and BRCA1 bind different phosphorylated proteins to fulfill distinct roles in the DNA damage response. The most striking difference in specificity is likely the high degree of selectivity that MDC1 shows for the C-terminal carboxylate of the gH2AX tail, which is precisely conserved at the +3 position with respect to the pSer in all H2AX orthologs from humans to yeast. Here we probe the structural basis for the differences in selectivity for the phosphopeptide C-terminal structure between BRCA1 and MDC1. We demonstrate, through structural and binding analysis of wild-type (WT) and mutant BRCT domains, characteristics that give MDC1 a large degree of specificity for the free C terminus of H2AX and in contrast, the seemingly more promiscuous nature of BRCA1.
RESULTS

Specificity of BRCA1 and MDC1 BRCT Domains for the C Termini of their Phosphopeptide Targets
The MDC1 BRCT domain specifically binds the gH2AX peptide tail, pSer-Gln-Glu-Tyr-COO À , in a manner that is highly dependent on the free C terminus at the +3 position. In contrast, BRCA1 has been shown to bind internal pSer-x-x-Phe peptide targets (as in BACH1 or CtIP) as well as the pSer-x-x-Phe motif at the C terminus of the protein (as in Abraxas). In order to compare the specificities of the BRCA1 and MDC1 BRCT domains for the chain termini at the +3 position, we used a competitive fluorescence polarization (FP) assay (Lokesh et al., 2006) . Each domain was bound to a fluorescein-labeled phosphopeptide target specific for that BRCT domain. The BACH1 target sequence was used for BRCA1, while the gH2AX tail peptide was used for MDC1. The labeled peptide was then competed off the BRCT domain using tetrapeptides containing the minimal recognition sequences: pSPTF for BRCA1 and pSQEY for MDC1. To test the role of the C terminus in peptide binding, competition experiments were performed with tetrapeptides containing either free carboxylate C termini or amidated (and therefore uncharged) C termini, and the inhibition constants (K i ) of each of the tetrapeptides was determined.
The results demonstrate that the tetrapeptide pSQEY-COO À competes very effectively for binding to MDC1, with a K i of 1.1 ± 0.1 mM (Figure 2A ). However, amidation of the C-terminal tail (pSQEY-CONH 2 ) reduced the K i approximately 50-fold, to 51 ± 1 mM. These findings are consistent with previously reported values from direct binding measurements (Stucki et al., 2005) . BRCA1 also showed a significant, although less dramatic, preference for a negatively charged C-terminal carboxylate at the +3 position. The tetrapeptide pSPTF-COO À inhibited binding of the fluorescein-labeled phosphopeptide very effectively (K i = 3.7 ± 0.3 mM) while the C-terminally amidated version (pSPTF-CONH 2 ) inhibited binding about 7-fold less efficiently (K i = 25 ± 5 mM) ( Figure 2B ). The micromolar K i value for the C-terminally amidated tetrapeptide is similar to previously reported values using direct binding measurements (Lokesh et al., 2006) .
Structural Mechanism of Recognition of Carboxyl Chain Termini by BRCA1
To investigate the differences in affinity of BRCA1 for a free carboxylate versus an amidated tail at the +3 position, we solved the crystal structures of both tetrapeptides bound to the BRCA1 BRCT domain. Complexes of BRCA1 BRCT bound to either tetrapeptide crystallized in the same space group as the unliganded BRCT domain (Williams et al., 2001 ) and the structures were determined to 2.70 Å ( Table 1 ). The amidated tetrapeptide (pSPTF-CONH 2 ) binds in a manner that is almost identical to that observed in the previously reported structures of BRCA1 BRCT bound to longer BACH1 peptides (Clapperton et al., 2004) ( Figure 1B ). In these structures, the backbone oxygen of the C-terminal amide makes a single hydrogen bond with the N3 of the conserved Arg1699. The peptide amide nitrogen rotates vertically above the oxygen, in a position that minimizes clashes with the terminal NH 2 of the guanidinium group of Arg1699. In the structure of free carboxylate peptide (pSPTF-COO À ) the C-terminal tail rotates slightly, so that the free carboxylate group can form a double salt bridge with the guanidinium group of Arg1699 ( Figure 2C ). The enhanced interaction of the free carboxylate group with Arg1699 compared with the amidated C terminus likely explains the increased K i of the free carboxylate tetrapeptide for the BRCA1 BRCT.
A Network of Salt Bridges Controls the Specificity of Recognition for Target Peptide Chain Termini A comparison of the structure of the MDC1 BRCT domain bound to the gH2AX tail (Stucki and Jackson, 2006) with the BRCA1 BRCT bound to the pSPTF-CONH 2 and pSPTF-COO À tetrapeptides suggests a mechanism that might explain the enhanced specificity of MDC1 for a free C-terminal carboxylate group ( Figures 2C and 2D) . In all the structures, a conserved arginine residue (Arg1699 in BRCA1 and Arg1933 in MDC1) contacts the backbone of the +3 residue. In the structures of BRCA1 and MDC1 bound to peptides with free carboxylate termini, the analogous arginine residues make similar, double salt bridge interactions with the peptide C-terminal carboxylate and are therefore likely key in recognition of the peptide C terminus. Differences in the environment of these arginine residues therefore may regulate the differential recognition of the peptide backbone. In both BRCT domains, the arginine is largely buried and is held in place through internal salt bridging interactions. In BRCA1, Arg1699 interacts with both Asp1840 and Glu1836. In MDC1, Glu2063 is equivalent to BRCA1 Glu1836; however, Asp1840 in BRCA1 has been replaced with a threonine in MDC1 (Thr2067). As a result, Arg1933 forms a dual salt bridge interaction with the conserved Glu2063. We suggest that the difference in the environment of the analogous arginine residues impacts recognition of the C terminus of the phosphopeptide chain. The arrangement observed in MDC1 allows the Arg1933 guanidinium group to make a dual salt bridging interaction with a highly favorable geometry. In contrast, in BRCA1, the shift in Glu1836 positions one of its carboxylate oxygens closer to the peptide +3 carboxylate ($4.5 Å in BRCA1 versus $5.5 Å in MDC1). This difference may help to explain the reduced selectivity of BRCA1 for a target with a free carboxylate group at the +3 position.
The structures of BRCA1 BRCT indicate that the interaction of Arg1699 with Asp1840 influences its interactions with Glu1836 and therefore may affect peptide binding selectivity. To test the importance of Asp1840 in BRCA1 and the analogous Thr2067 in MDC1, we created BRCA1 and MDC1 mutants in which these residues were exchanged for the corresponding residue in the other BRCT protein, generating the mutants BRCA1 D1840T and MDC1 T2067D. The effects of these mutations on the structures and peptide binding specificities of the mutant proteins were determined.
Structure and Peptide Binding Specificity of BRCA1 D1840T
The BRCA1 D1840T mutant in complex with both the pSPTF-CONH 2 and pSPTF-COO À peptides was crystallized and the structures were determined to 2.8 and 3.0 Å resolution, respectively (Table 1 ). The structures reveal that the D1840T substitution facilitates an MDC1-like interaction between Arg1699 and Glu1836 in which the two side chains contact one another through double salt bridging interactions ( Figures 3A and 3B ). In the BRCA1-BRCT/pSPTF-COO À structure, the C-terminal peptide terminus rotates almost completely horizontal relative to Arg1699, resulting in a more optimal salt bridge compared to the WT structure.
FP was used to assess the effect of the BRCA1 D1840T mutation on recognition of the pSPTF-COO À and pSPTF-CONH 2 peptides ( Figure 3C ). The K i of D1840T BRCA1 for pSPTF-CONH 2 increases to 12 ± 2 mM, while the K i for pSPTF-COO À increases to 1.6 ± 0.3 mM. The results indicate a subtle 2-fold increase in the binding affinity of the mutant for either tetrapeptide compared to WT BRCA1. In spite of the fact that 
, where I hkl is the integrated intensity of a given reflection. b Values in parentheses are for the highest resolution shell. the mutation has induced a more MDC1-like conformation in the mutant, there is no corresponding increase in the selectivity of the mutant for peptides with a free C-terminal carboxylate.
Structure and Peptide Binding Specificity of MDC1 T2067D FP spectroscopy was used to characterize the changes in affinity and specificity induced by the T2067D mutation in MDC1 ( Figure 4A ). Direct binding experiments suggested a small, 2-fold decrease in the affinity of the T2067D mutant for that of the fluorescein-labeled gH2AX peptide compared to WT (data not shown). However, no significant differences between the mutant and WT were observed in the context of competition studies using the gH2AX tetrapeptide (K i = 1.4 ± 0.2 mM versus 1.1 ± 0.1 mM), suggesting the mutation induces little if any change in recognition of the gH2AX C-terminal carboxylate. In contrast, the amidated gH2AX peptide (pSQEY-CONH 2 ) was a much more effective inhibitor of MDC1 T2067D than WT MDC1, with a nearly 4-fold enhanced K i compared to the WT. Thus unlike BRCA1 D1840T, MDC1 T2067D induces a significant change in the specificity of the BRCT domain for the C terminus of the peptide tail. While WT MDC1 shows a 50-fold preference for the gH2AX tail with a free C-terminal carboxylate versus an amidated end, the T2067D mutant shows only a 10-fold preference, very similar to that observed for BRCA1.
To understand the structural basis for this change in specificity, we crystallized and determined the structure of MDC1 T2067D bound to the gH2AX tetrapeptide pSQEY-CONH 2 at 1.33 Å resolution. This crystal form is isomorphous with that of the unliganded MDC1 BRCT domain previously determined (Lee et al., 2005) and contains two BRCT-tetrapeptide complexes in the asymmetric unit (Table 1) . One complex in the asymmetric unit reveals an interaction between Arg1933 and Asp2067 that is similar to the salt bridging pattern of the analogous residues in BRCA1 ( Figure 4B ). However, unlike BRCA1, Glu2063 adopts a rotamer not observed in either WT MDC1 or BRCA1 such that it no longer directly contacts Arg1933. Instead, a pair of water molecules bind in the space created between Arg1933, Glu2063, and Asp2067 and the peptide C terminus. This arrangement allows the Arg to shift lower in the binding pocket compared to the WT, increasing the distance between the amidated C terminus of the peptide and the Arg1933 guanidium, while maintaining hydrogen bonding interactions with the peptide main chain carbonyl group. The water molecules may also stabilize peptide binding through bridging hydrogen bonds between the terminal amide of the peptide and Glu2063. In the other complex in the asymmetric unit, a second set of alternative conformations are observed for Glu2063 and Asp2067. In this alternative conformation, it is Glu2063 that forms a direct salt bridge contact to Arg1933 in a manner that is similar to WT BRCA1, while the Asp2067 swings away from the Arg1933 and contacts Lys2071 (see Figure S1B available online). Thus, the T2067D mutation in MDC1 does induce a more BRCA1-like recognition of phosphopeptides, through a relaxation of the requirement for a C-terminal main chain carboxylate at the peptide +3 position. This is accomplished through a shift to a more BRCA1-like conformation in the mutant, as well as an increase in the flexibility and hydration of the recognition surface, which results in a significant enhancement in the affinity of the mutant MDC1 for the C-terminally amidated phosphopeptide.
The MDC1 BRCT Is Highly Selective for Ser139-Phosphorylated gH2AX and Does Not Bind Alternative Phosphopeptide Targets Recent studies have demonstrated that the +3 C-terminal tyrosine residue of H2AX (Tyr142) is phosphorylated in a manner that is coordinated with the phosphorylation status of Ser139 (Cook et al., 2009; Xiao et al., 2009) . In undamaged chromatin, Tyr142 is phosphorylated by the WSTF component of the WSTF-SNF2H (WICH) chromatin remodeling complex (Xiao et al., 2009) . In response to a DNA double strand break, this phosphorylation is lost due to the action of the EYA phosphatase, and H2AX is subsequently phosphorylated at Ser139 to allow the subsequent binding of MDC1. The balance of these two phosphorylation events may help direct the damaged cell to either an MDC1-dependent DNA repair/cell survival pathway or an apoptotic pathway (Cook et al., 2009) .
We used FP spectroscopy to quantitate the effects of Tyr142 phosphorylation on interactions with the MDC1 BRCT domain. Our results show a profound, >300-fold reduction in the affinity of MDC1 BRCT-gH2AX interactions upon phosphorylation of Tyr142 ( Figure 5A ), which agrees with the results of peptide pull-down experiments (Xiao et al., 2009 ). To understand the structural basis for this discrimination, we modeled the pSer/ pTyr tetrapeptide (pSQEpY-COO À ) into the MDC1 binding pocket ( Figure 5B ). The modeling suggests that the phosphate of pTyr142 would clash with either the MDC1 specificity loop or the absolutely conserved Gln140 depending on the pTyr rotamer.
The MDC1 BRCT domain has also been shown to specifically bind the C-terminally phosphorylated tail of topoisomerase IIa, an interaction that specifically regulates the DNA decatenation cell cycle checkpoint (Luo et al., 2009 ). The sequence of the topoisomerase IIa peptide (pSDEDDLF-COO À ) is unrelated to that of gH2AX. We used FB to test for interactions of this unusual target with the MDC1 BRCT but were unable to detect any binding activity (data not shown). The previously reported binding activity may therefore represent an interaction that requires additional contacts, perhaps involving other regions of the proteins or additional protein cofactors.
DISCUSSION
Our results provide structural insight into the central role played by a conserved arginine (BRCA1 Arg1699 and MDC1 Arg1933) in the recognition of the phosphopeptide +3 residue by tandem BRCT repeats. We show that the details of salt bridging interactions between this arginine and acidic residues that bridge the interface between the BRCT repeats modulate the orientation of this residue and its interactions with the phosphopeptide backbone.
Arg1699 likely plays an especially critical role in BRCA1 function as three distinct missense variants (R1699W, R1699L, and R1699Q) have been uncovered at this position through breast cancer screening programs (see http://research.nhgri.nih.gov/ bic/ for a listing of BRCA1 variants). Pedigree analysis suggests both R1699W and R1699Q are associated with an increased cancer risk, and these variants are functionally defective in a BRCA1 transcription assay (Vallon-Christersson et al., 2001) and in their ability to bind a pSer-x-x-Phe peptide in a pulldown assay . The R1699Q mutation is particularly interesting, since it should be able to participate in hydrogen bonding interactions with the peptide +3 backbone that could mimic the salt bridging observed in the WT. The fact that this mutant shows peptide binding defects indicates that the ability to form salt bridges, either with the phosphopeptide or with Glu1836 and Asp1840, and not simply hydrogen bonding, is critical for its function. Interestingly, an E1836K variant has also been found through breast cancer screening. We suggest that this variant could perturb the orientation of Arg1699 through electrostatic repulsion with the Lys1836 and thereby impact phosphopeptide recognition. Arg1933 in MDC1, like Arg1699 in BRCA1, is also necessary for recognition of the phosphopeptide main chain at the +3 position. In spite of the structural similarity of the BRCA1-and MDC1-phosphopeptide complexes, MDC1 shows a dramatic, 50-fold selectivity for peptides with a terminal main chain carboxylate at the +3 position compared to peptides with an amidated C terminus. In contrast, BRCA1 shows a much reduced, $7-fold selectivity for a main chain carboxylate at the peptide +3 position ( Figure 6A ). Introduction of a T2067D substitution in MDC1 induces a significant increase in the affinity of a C-terminally amidated gH2AX phosphopeptide such that the binding preference for a C-terminal carboxylate versus an amide drops to 10-fold ( Figure 6A ). The high resolution structure of this variant in two different crystal environments reveals an overall more BRCA1-like conformation and additional flexibility near Arg1933. This relaxation of the MDC1 structure allows a shift in the position of the Arg1933 guanidium group that relieves the electrostatic repulsion with the terminating amide group at the phosphopeptide C terminus that would otherwise occur.
Interestingly, the complimentary substitution in BRCA1, D1840T, does not induce an MDC1-like enhancement in the preference for a main chain carboxylate at the phosphopeptide +3 position. The reason for this likely is explained by differences in the way in which the +3 tyrosine is positioned in the specificity pocket of BRCA1 and MDC1 ( Figure 6B ). In both proteins, key interactions with the +3 side chain are made by residues from the b1 0 -a1 00 loop. Met1775 in BRCA1 makes the closest contact to the phenylalanine side chain at +3, while Pro2009 contacts the +3 tyrosine side chain in MDC1. In MDC1, these interactions place the +3 Tyr carboxylate such that it contacts the Arg1933 guanidinium group in a nearly co-planar orientation. In the BRCA1 complex, the +3 Phe sits lower in its binding pocket and its main chain approaches the Arg1699 guanidinium in a more orthogonal manner, $20 offset from the angle of approach observed in MDC1. The more favorable hydrogen bonding geometry associated with the in-line approach of the C-terminal peptide carboxylate on the Arg1933 guanidinium group in MDC1 explains the enhanced affinity of MDC1 for the carboxylated chain terminus compared to BRCA1. In contrast, the BRCA1 orientation provides more flexibility, allowing for binding of extended peptide chains. In the BRCA1 orientation, a small rotation of the c torsion angle of the C-terminal residue is sufficient to shift the amidated C terminus of the peptide away from the Arg1699 guanidinium group. However, in the MDC1 orientation a similar rotation is not sufficient to minimize the clash between the backbone and the Arg1933 guanidinium without a more significant reorganization of the interface. This likely explains MDC1's strong discrimination against binding peptide targets with extensions beyond the +3 position (Lee et al., 2005; Stucki et al., 2005) .
The precise and rather rigid recognition of the peptide C-terminal carboxylate is central to the ability of MDC1 to mediate interactions with H2AX and for the modulation of these interactions through phosphophorylation of H2AX at Tyr142. pTyr142 is an important H2AX mark in undamaged chromatin, where one of its roles is to likely block binding of MDC1 (Xiao et al., 2009; Cook et al., 2009) . The anchoring of the Tyr142 through strong interactions with Arg1933, as well as van der Waals contacts with Pro2009, fixes the tyrosine on MDC1 such that its phosphorylation cannot be accommodated in the binding pocket.
The recognition of the C-terminally phosphorylated tail of H2A/H2AX by BRCT proteins in the DNA damage response is conserved throughout eukaryotes. In both S. cerevisiae and S. pombe, 53BP1 orthologs specifically bind the gH2A tail (.ApSQEL-COO À ) via their tandem BRCT repeats (Hammet Kilkenny et al., 2008) . The fact that the position of the H2A C terminus is precisely conserved suggests that this may be a dominant specificity determinant in the yeast systems. However, the crystal structure of the BRCT domain of the S. pombe 53BP1 ortholog Crb2 bound to the gH2A tail indicates that the gH2A C-terminal carboxylate does not contact Crb2 Arg616 (analogous to Arg1699 in BRCA1). It has been suggested that in this case chromatin recognition may not only involve BRCT-gH2A interactions but may also rely on interactions of the adjacent tandem Tudor domain with lysine-methylated histones (Kilkenny et al., 2008) . Intriguingly, the 53BP1 tandem BRCT domain also binds gH2AX in vitro, raising the possibility that 53BP1 may recognize nucleosomes presenting methyllysine and gH2AX histone tails during the DNA damage response.
Given the conformationally restrained yet structurally diverse nature of the BRCA1 and MDC1 peptide-binding grooves, it may be possible to develop inhibitors that are specific for a particular BRCT domain. Indeed, preliminary studies have identified both peptide and small molecule inhibitors of the BRCA1 BRCT domain (Lokesh et al., 2007 (Lokesh et al., , 2006 Simeonov et al., 2008 ). Here we have defined an important determinant of specificity between BRCA1 and MDC1 that could be utilized in the rational design of specific BRCT inhibitors. Such inhibitors could provide useful tools for the study of the role of specific BRCT domains and potentially could provide new routes to modulate the DNA damage response in the treatment of cancer.
EXPERIMENTAL PROCEDURES
BRCT Plasmids and Purification BRCA1 BRCT WT (residues 1646-1859), used in both FP and crystallization experiments, was expressed as an untagged recombinant protein in the plasmid pLM1-CD6. This plasmid was used as a template to clone BRCA1 BRCT D1840T using PCR mutagenesis, which was then ligated into the same plasmid. Both proteins were expressed in E. coli BL21 Gold (Invitrogen) for 15 hr at 22 C and purified as previously described (Williams et al., 2001 ).
Purified BRCA1 BRCT was buffer exchanged into crystallization buffer [5 mM Tris HCl (pH 7.5) and 400 mM NaCl] using spin concentration and quantified using a BCA assay. MDC1 WT (1891-2089) was expressed as a maltose binding protein fusion protein using pKM596 (NEB). This construct was then used as a template to clone MDC1 BRCT T2067D using PCR mutagenesis and Gateway (Invitrogen). The proteins were overexpressed in E. coli BL21 Gold at 20 C for 16 hr, and the cell pellets were then resuspended and sonicated. The lysate was cleared by ultracentrifugation at 40,000 3 g for 1 hr. The cleared lysate was further purified with an amylose resin affinity column (NEB). MDC1 used for crystallization was then cleaved using Actev protease (Invitrogen) and the maltose binding protein tag was removed using anion exchange chromatography. Purified MDC1 BRCT was buffer exchanged into crystallization buffer [10 mM TrisHCl (pH 7.5), 150 mM NaCl, and 1 mM DTT] and quantified using a BCA assay.
Fluorescence Polarization
Fluorescein-labeled peptides were obtained from the Alberta Peptide Institute and are as follows: BACH1 peptide, fluorescein-GGSRSTpSPTFNK-CONH 2 ; gH2AX peptide, fluorescein-KKATQApSQEY-COO À . Fluorescein peptide binding to BRCA1 and MDC1 BRCT domains was verified by titrating an increasing concentration of protein into a constant concentration of labeled peptide. Fluorescein fluorescence was excited at a wavelength of 485 nm and the emission was measured at 538 nm on a PerkinElmer Envision plate reader. The change in polarization was graphed as a function of the log of the protein concentration, and the dissociation constant (K D ) was obtained from the resulting sigmoidal curve. The fluorescein-labeled peptide was shown to have a similar K D as previously reported values using both FP and direct binding methods ( Figure S2 ) (Lokesh et al., 2006; Stucki et al., 2005) . Binding constants of the tetrapeptides were then determined using a competition assay, where the ability of the tetrapeptide to compete off the labeled peptide was measured. The concentration of protein used in the competition assay was determined based on the K D of the labeled peptide to its corresponding protein. The IC 50 was obtained from the competition assay and the K i was then calculated using the Coleska-Wang equation (Nikolovska-Coleska et al., 2004) . For all assays, a concentration of 100 nM of labeled peptide was used in a reaction volume of 20 ml. Accurate concentrations of the tetrapeptides were determined by amino acid analysis.
Crystallization and Data Collection
The BRCA1 BRCT WT in complex with pSPTF-CONH 2 was crystallized using the sitting drop vapor diffusion method. BRCA1 BRCT WT was incubated on ice with an equimolar amount of pSPTF-CONH 2 for $3 hr. Crystals were grown by mixing 2 ml of BRCA1 BRCT WT [10 mg ml À1 protein, 5 mM Tris-HCl (pH 7.5), and 400 mM NaCl] with 1 ml of well solution [0.1 M Tris-HCl (pH 7.3), 0.4 M Li 2 SO 4 , and 10 mM NiCl 2 ]. BRCA1 BRCT WT in complex with pSPTF-COO À grew in identical conditions. Crystals of BRCA1 BRCT D1840T in complex with both tetrapeptides grew in very similar conditions to the WT protein, but preferred a pH between 8.3 and 8.5. Crystals were present in the drops after several days and were large enough to loop after approximately 2 weeks. Crystals were cryoprotected in well solution supplemented with 26% glycerol and approximately 250 mM tetrapeptide, and then looped and flash frozen using liquid nitrogen. Data were collected at beamline CMCF 08ID-1 at the Canadian Light Source. The MDC1 BRCT T2067D in complex with pSQEY-CONH 2 was crystallized using the hanging drop vapor diffusion method. MDC1 BRCT T2067D was incubated on ice with an equimolar concentration of pSQEY-CONH 2 for approximately three hours. Crystals were grown by adding 1 ml of MDC1 BRCT T2067D (7.5 mg ml À1 , 10 mM Tris-HCl pH 7.5, 100 mM NaCl, 1 mM DTT) and 1 ml well solution (24% PEG 8000 and 0.1 M HEPES pH 8.0). Plates were present after approximately one week, and were looped using Mitegen MicroMesh. Crystals were cryoprotected in well solution supplemented with 26% glycerol and approximately 250 mM pSQEY-CONH 2 . Data were collected at beamline 8.3.1 at the Advanced Light Source.
Model Building and Refinement BRCA1 WT and D1840T (1846-1859) complex structures were indexed and scaled using HKL2000 (Otwinowski and Minor, 1997) . Crystals grew in the space group P6 1 22 with one molecule in the asymmetric unit. The BRCA1 BRCT structures were solved with molecular replacement (Phaser) (McCoy, 2007) using a BRCA1/BACH1 peptide complex (PDB ID: 1T15) as starting model. The first three residues (1846-1848) were not visible in the electron density. Electron density for the tetrapeptides was clear and the ligand was modeled in to the phosphate binding pocket. The occupancies of the tetrapeptides in each model were adjusted to 70%-80% to give reasonable B factors. Structures were refined using TLS and restrained refinement in REFMAC (Murshudov et al., 1997; Winn et al., 2001 Winn et al., , 2003 . The TLS parameters were defined using chain A as the single TLS group. Electron densities of the +3 binding region shows a change in side chain positions as a result of the corresponding mutation previously described (D1840T) ( Figure S3 ). Geometric restraints were tightened from program defaults to maintain correct geometry. A strong peak located above the side chains of His1805 and His1673 of a symmetry mate was modeled as a nickel cation coordinating to the imidazole groups as observed in the previous unbound BRCA1 WT structure (Williams et al., 2001) . Although three other waters were expected to be coordinated to the nickel, it was not possible to satisfactorily model them into the BRCA1 WT complex structures. However, in the BRCA1 D1840T complex structures, two waters coordinated to the nickel were modeled with reasonable geometry. In addition to the nickel peak, another strong peak was located near the N terminus of the tetrapeptide. Since both sulfate and chloride were present in the crystallization conditions, it was likely that an anion was bound to the ammonium cation at the N terminus of the tetra peptide. Chloride was the only ion that resulted in satisfactory geometry and was refined at the same occupancy as the tetrapeptide. Model building was done using the program Coot (Emsley and Cowtan, 2004) .
MDC1 T2067D (1891-2089) was indexed and scaled using HKL2000. Crystals grew in the P2 1 2 1 2 1 space group and phases were solved by molecular replacement using a previous MDC1 BRCT structure (PDB ID: 2ADO). The electron density for pSQEY-CONH 2 was clear, and the ligand was modeled in easily. The orientation of Glu2063 and Asp2067 in chain A was clear at 1.35 Å ( Figure S2A ). The electron density around chain B indicated an alternate conformation, in addition to the one in chain A, where Glu2067 interacted with Arg1933 while Asp2067 rotates away ( Figure S2B ). However, given the two conformations present in chain B, the electron density was not quite as clear.
The structure was refined with TLS and restrained refinement using anisotropic B factors in REFMAC. For TLS, the main chain of each molecule in the asymmetric unit and each tetrapeptide were defined as individual TLS groups. Residues 1891-2089 were modeled in to chain B, but the final six residues did not have clear electron density in chain A and could not be modeled.
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